1. A data store system, comprising:
at least one function block having store data to be stored;
a storage section for storing the store data transferred from the function block;
a bus having a bit width of a predetermined number of bits where the function block and the storage section are connected; and
a controller for sending a store period clock to the function block and the storage section when the store data is to be transferred from the function block to the storage section,
wherein the function block includes:
a first data-retention section for retaining the store data; and
a first store-processing controller for reading the store data a predetermined number of bits at a time within the bit width of the bus from the first data-retention section in synchronization with the store period clock, and sending the read store data to a line of the bus assigned to each function block, and
wherein the storage section includes:
a second data-retention section for retaining the store data transferred from the function block through the bus; and
a second store-processing controller for reading the store data from the bus in synchronization with the store period clock, and storing the read store data in the second data-retention section.
2. The data store system as claimed in claim 1, comprising:
a bus assignment setting section for setting, for each function block, the predetermined number of bits of the store data sent to the bus every clock cycle of the store period clock.
3. The data store system as claimed in claim 2,
wherein the first store-processing controller sends a signal indicating a state of a store completion flag that indicates whether or not sending of the store data read from the first data-retention section to the bus is complete to the bus assignment setting section, and
wherein the bus assignment setting section sets the predetermined number of bits of the store data sent to the bus for each function block in response to the state of the store completion flag indicated by the signal sent from the first store-processing controller of the function block.
4. The data store system as claimed in claim 1,
wherein the function block includes a bus assignment setting section for setting in the first store-processing controller, the predetermined number of bits of the store data sent to the bus every clock cycle of the store period clock.
5. The data store system as claimed in claim 1,
wherein the data store system comprises a plurality of the function blocks,
wherein the plurality of function blocks are classified into a plurality of groups, and
wherein the controller sends the store period clock so that sending times do not overlap with each other, at a different timing for each group of the plurality of function blocks.
6. A data restoration system, comprising:
at least one function block;
a storage section for storing restoration data required for the function block to resume the operation;
a bus having a bit width of a predetermined number of bits where the function block and the storage section are connected; and
a controller for sending a restoration period clock to the function block and the storage section when the restoration data stored in the storage section is to be transferred to the function block,
wherein the storage section includes:
a first data-retention section for retaining the restoration data; and
a first restoration-processing controller for reading the restoration data from the first data-retention section in synchronization with the restoration period clock, and sending the read restoration data to a line of the bus assigned to each function block, and
wherein the function block includes:
a second data-retention section for retaining the restoration data transferred from the storage section through the bus; and
a second restoration-processing controller for reading the restoration data a predetermined number of bits at a time from a predetermined line of the bus assigned to each function block in synchronization with the restoration period clock, and storing the read restoration data in the second data-retention section.
7. The data restoration system as claimed in claim 6, comprising:
a bus assignment setting section for setting, for each function block, the predetermined number of bits of the restoration data read from the bus every clock cycle of the restoration period clock.
8. (canceled)
9. The data restoration system as claimed in claim 7,
wherein the second restoration-processing controller sends a signal indicating a state of a restoration completion flag that indicates whether or not receiving of the restoration data transferred from the storage section through the bus is complete to the bus assignment setting section, and
wherein the bus assignment setting section sets the predetermined number of bits of the restoration data read from the bus for each function block in response to the state of the restoration completion flag indicated by the signal sent from the second restoration-processing controller of the function block.
10. The data restoration system as claimed in claim 6,
wherein the function block includes a bus assignment setting section for setting in the second restoration-processing controller, the predetermined number of bits of the restoration data read from the bus every clock cycle of the restoration period clock.
11. The data restoration system as claimed in claim 6,
wherein the data restoration system comprises a plurality of the function blocks,
wherein the plurality of function blocks are classified into a plurality of groups, and
wherein the controller sends the restoration period clock so that read times do not overlap with each other, at a different timing for each group of the plurality of function blocks.
12. A data store method performed by a data store system comprising:
at least one function block having store data to be stored;
a storage section for storing the store data transferred from the function block;
a bus having a bit width of a predetermined number of bits where the function block and the storage section are connected; and
a controller for sending a store period clock to the function block and the storage section when the store data is to be transferred from the function block to the storage section,
wherein the data store method comprises:
sending by the controller the store period clock to the function block and the storage section,
sending by the function block the store data a predetermined number of bits at a time within the bit width of the bus to a line of the bus assigned to each function block in synchronization with the store period clock, and
reading by the storage section the store data from the bus in synchronization with the store period clock, and storing the read store data.
13. A data restoration method performed by a data restoration system comprising:
at least one function block;
a storage section for storing restoration data required for the function block to resume the operation;
a bus having a bit width of a predetermined number of bits where the function block and the storage section are connected; and
a controller for sending a restoration period clock to the function block and the storage section when the restoration data stored in the storage section is to be transferred to the function block,
wherein the data restoration method comprises:
sending by the controller the restoration period clock to the function block and the storage section,
sending by the storage section the restoration data to a line of the bus assigned to each function block in synchronization with the restoration period clock, and
reading by the function block the restoration data a predetermined number of bits at a time from a predetermined line of the bus assigned to each function block in synchronization with the restoration period clock, and storing the read restoration data.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. An amorphous form of 9-nitrocamptothecin produced by grinding or pulverizing a polymorphic form of 9-nitrocamptothecin, wherein the polymorphic form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 6.7, 12.5, 14.0 and 23.9 for Cu K radiation of wavelength 1.5406 Angstrom.
2. The amorphous form of 9-nitrocamptothecin according to claim 1, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 6.7, 12.5, 14.0 and 23.9 that are substantially broader than the corresponding diffraction lines of the polymorphic form for Cu K radiation having a wavelength of 1.5406 Angstrom.
3. The amorphous form of 9-nitrocamptothecin according to claim 1, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern without discernable diffraction lines beyond noises.
4. A pharmaceutical composition comprising:
a pharmaceutical carrier; and
an amorphous form of 9-nitrocamptothecin according to claim 1.
5. An amorphous form of 9-nitrocamptothecin produced by grinding or pulverizing a polymorphic form of 9-nitrocamptothecin, wherein the polymorphic form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 4.8, 14.2, 19.1 and 26.8 for Cu K radiation of wavelength of 1.5406 Angstrom.
6. The amorphous form of 9-nitrocamptothecin according to claim 5, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 4.8, 14.2, 19.1 and 26.8 that are substantially broader than the corresponding diffraction lines of the polymorphic form for Cu K radiation having a wavelength of 1.5406 Angstrom.
7. The amorphous form of 9-nitrocamptothecin according to claim 5, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern without discernable diffraction lines beyond noises.
8. A pharmaceutical composition comprising:
a pharmaceutical carrier; and
an amorphous form of 9-nitrocamptothecin according to claim 5.
9. An amorphous form of 9-nitrocamptothecin produced by grinding or pulverizing a polymorphic form of 9-nitrocamptothecin, wherein the polymorphic form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 11.0, 14.0, 16.4, and 27.0 for Cu K radiation of wavelength of 1.5406 Angstrom.
10. The amorphous form of 9-nitrocamptothecin according to claim 9, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 11.0, 14.0, 16.4, and 27.0 that are substantially broader than the corresponding diffraction lines of the polymorphic form for Cu K radiation having a wavelength of 1.5406 Angstrom.
11. The amorphous form of 9-nitrocamptothecin according to claim 9, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern without discernable diffraction lines beyond noises.
12. A pharmaceutical composition comprising:
a pharmaceutical carrier; and
an amorphous form of 9-nitrocamptothecin according to claim 9.
13. An amorphous form of 9-nitrocamptothecin produced by grinding or pulverizing a polymorphic form of 9-nitrocamptothecin, wherein the polymorphic form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 5.4, 10.6 and 26.5 for Cu K radiation having a wavelength of 1.5406 Angstrom.
14. The amorphous form of 9-nitrocamptothecin according to claim 13, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 5.4, 10.6 and 26.5 that are substantially broader than the corresponding diffraction lines of the polymorphic form for Cu K radiation having a wavelength of 1.5406 Angstrom.
15. The amorphous form of 9-nitrocamptothecin according to claim 13, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern without discernable diffraction lines beyond noises.
16. A pharmaceutical composition comprising:
a pharmaceutical carrier; and
an amorphous form of 9-nitrocamptothecin according to claim 13.
17. An amorphous form of 9-nitrocamptothecin produced by grinding or pulverizing a polymorphic form of 9-nitrocamptothecin, wherein the polymorphic form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 10.5, 12, 13.25, 16.0, and 24.5 for Cu K radiation having a wavelength of 1.5406 Angstrom.
18. The amorphous form of 9-nitrocamptothecin according to claim 17, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 10.5, 12, 13.25, 16.0, and 24.5 that are substantially broader than the corresponding diffraction lines of the polymorphic form for Cu K radiation having a wavelength of 1.5406 Angstrom.
19. The amorphous form of 9-nitrocamptothecin according to claim 17, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern without discernable diffraction lines beyond noises.
20. A pharmaceutical composition comprising:
a pharmaceutical carrier; and
an amorphous form of 9-nitrocamptothecin according to claim 17.
21. An amorphous form of 9-nitrocamptothecin produced by grinding or pulverizing a polymorphic form of 9-nitrocamptothecin, wherein the polymorphic form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 7.4 and 22.5 for Cu K radiation having a wavelength of 1.5406 Angstrom.
22. The amorphous form of 9-nitrocamptothecin according to claim 21, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 7.4 and 22.5 that are substantially broader than the corresponding diffraction lines of the polymorphic form for Cu K radiation having a wavelength of 1.5406 Angstrom.
23. The amorphous form of 9-nitrocamptothecin according to claim 21, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern without discernable diffraction lines beyond noises.
24. A pharmaceutical composition comprising:
a pharmaceutical carrier; and
an amorphous form of 9-nitrocamptothecin according to claim 21.
25. An amorphous form of 9-nitrocamptothecin produced by grinding or pulverizing a polymorphic form of 9-nitrocamptothecin, wherein the polymorphic form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 8.0 and 25.7 for Cu K radiation of wavelength 1.5406 Angstrom.
26. The amorphous form of 9-nitrocamptothecin according to claim 25, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern with diffraction lines at 2 values 8.0 and 25.7 that are substantially broader than the corresponding diffraction lines of the polymorphic form for Cu K radiation having a wavelength of 1.5406 Angstrom.
27. The amorphous form of 9-nitrocamptothecin according to claim 25, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern without discernable diffraction lines beyond noises.
28. A pharmaceutical composition comprising:
a pharmaceutical carrier; and
an amorphous form of 9-nitrocamptothecin according to claim 25.
29. An amorphous form of 9-nitrocamptothecin produced by removing methanol by evaporation from a 9-nitrocamptothecin in methanol solution.
30. The amorphous form of 9-nitrocamptothecin according to claim 29, wherein the amorphous form is characterizable as having an X-ray powder diffraction pattern without discernable diffraction lines beyond noises.
31. A pharmaceutical composition comprising:
a pharmaceutical carrier; and
an amorphous form of 9-nitrocamptothecin according to claim 29.
32. A method for treating a patient having a neoplastic disease, the method comprising: administering to a patient a pharmaceutically effective amount of the pharmaceutical composition of claim 4, 8, 12, 16, 20, 24, 28, or 31.
33. The method according to claim 32, wherein the neoplastic disease is selected from restenosis, benign tumor, cancer, hematological disorders, and atherosclerosis.
34. The method according to claim 33, wherein the benign tumor is selected from the group consisting of hemangiomas, hepatocellular adenoma, cavernous haemangioma, focal nodular hyperplasia, acoustic neuromas, neurofibroma, bile duct adenoma, bile duct cystanoma, fibroma, lipomas, leiomyomas, mesotheliomas, teratomas, myxomas, nodular regenerative hyperplasia, trachomas and pyogenic granulomas.
35. The method according to claim 33, wherein the cancer is selected from the group consisting of breast cancer, skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer, brain cancer, cancer of the larynx, gallbladder, pancreas, rectum, parathyroid, thyroid, adrenal, neural tissue, head and neck, colon, stomach, bronchi, kidneys, basal cell carcinoma, squamous cell carcinoma of both ulcerating and papillary type, metastatic skin carcinoma, osteo sarcoma, Ewing’s sarcoma, veticulum cell sarcoma, myeloma, giant cell tumor, small-cell lung tumor, gallstones, islet cell tumor, primary brain tumor, acute and chronic lymphocytic and granulocytic tumors, hairy-cell tumor, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neuronms, intestinal ganglloneuromas, hyperplastic corneal nerve tumor, marfanoid habitus tumor, Wilm’s tumor, seminoma, ovarian tumor, leiomyomater tumor, cervical dysplasia and in situ carcinoma, neuroblastoma, retinoblastoma, soft tissue sarcoma, malignant carcinoid, topical skin lesion, mycosis fungoide, rhabdomyosarcoma, Kaposi’s sarcoma, osteogenic and other sarcoma, malignant hypercalcemia, renal cell tumor, polycythermia vera, adenocarcinoma, glioblastoma multiforma, leukemias, lymphomas, malignant melanomas, and epidermoid carcinomas.
36. The method of claim 33, wherein the hematological disorders are selected from the group consisting of acute myeloid leukemia, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, the myelodysplastic syndromes, and sickle cell anemia.